| Article | Added |
|---|
| ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS Disorders | 02-03-12 |
| Statement from Susan G. Komen for the Cure Board of Directors and Founder and CEO | 02-03-12 |
| GENFIT Corp. Release: The GFT505-210-6 Study Reaches All Its Efficacy Objectives With No Adverse Effects
| 02-03-12 |
| Positive Data Presented on Athersys, Inc.' MultiStem to Treat Stroke | 02-03-12 |
| Watson Pharmaceuticals, Inc. Provides Update on Generic Lidoderm(R) Application | 02-03-12 |
| Talon Therapeutics, Inc.' Product Candidate Marqibo(R) to be Assessed by Oncologic Drug Advisory Committee (ODAC) on March 21, 2012 With a PDUFA Date of May 13, 2012 | 02-03-12 |
| MannKind Corporation Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock | 02-03-12 |
| CORRECTING and REPLACING Cook Medical Launches Zenith?? Low Profile Endovascular Graft in Canada | 02-03-12 |
| Bristol-Myers Squibb Company Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibetex Therapeutics Inc. | 02-03-12 |
| MannKind Corporation Receives Commitment from the Mann Group to Acquire 31,250,000 Shares of Common Stock | 02-03-12 |
| Synthetic Genetics and Integrated DNA Technologies Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology | 02-03-12 |
| OptiNose AS Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology | 02-03-12 |
| Exelixis, Inc. Release: Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma | 02-03-12 |
| CSL Behring Release: International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients With Severe Hemophilia B | 02-03-12 |
| OncoGenex Pharmaceuticals Inc. Release: Clinical Data on OGX-427 Presented at the ASCO 2012 Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer | 02-02-12 |
| Diamyd Medical AB's Phase III Study Published in The New England Journal of Medicine | 02-02-12 |
| Ipsen??'s Fourth Quarter and Full year 2011 Sales and Other Significant Developments | 02-02-12 |
| Mylan Inc. Receives Tentative FDA Approval for Generic Version of Lipitor(R) | 02-02-12 |
| ThromboGenics Ltd. Announces That the FDA Intends to Grant Ocriplasmin Priority Review | 02-02-12 |
| Dynavax Technologies Corporation Reports on Heplisav(TM) Pre-BLA Meeting With FDA | 02-02-12 |
| Bedford Laboratories Issues a Voluntary Nationwide Patient Level Recall of Acetylcysteine Solution, USP, Lot 1877093 | 02-02-12 |
| Acsis, Inc. Releases the latest ProducTrak??? Solutions | 02-02-12 |
| Biotechnology Industry Organization (BIO) Testifies on Importance of Prompt Enactment of PDUFA V Recommendations | 02-02-12 |
| Verastem, Inc. Release: Underwriters Exercise Over-Allotment Option for Verastem Initial Public Offering | 02-02-12 |
| Pozen, Inc. Release: Preventive Aspirin Use Less Than Optimal in Stroke Survivors Despite Clinical Guidelines | 02-02-12 |
| AHF Calls for Congressional Investigation and Shake Up at FDA | 02-02-12 |
| Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant??? - "Be Ready in an Instant" | 02-02-12 |
| Affinium Pharmaceuticals Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections | 02-01-12 |
| Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections | 02-01-12 |
| Halozyme Therapeutics, Inc. Release: HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial | 02-01-12 |
| Ablynx Receives Another EUR $5 Million Milestone as Boehringer Ingelheim Corporation Selects Nanobody Candidate for Pre-Clinical Development | 02-01-12 |
| AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc.'s Sutent??in Gleevec??-resistant GIST | 02-01-12 |
| American Heart Association Release: Experimental Drug Reduces "Second Stroke" After Aneurysm Rupture | 02-01-12 |
| ErgoD2 Achieves Important Safety Milestone for Entia Biosciences | 02-01-12 |
| American Heart Association Release: Infections in Childhood Linked to High Risk of Ischemic Stroke | 02-01-12 |
| Infectious Disease Research Institute (IDRI) Supports the First Phase 1 Human Hookworm Vaccine Clinical Trial | 02-01-12 |
| Starpharma Holdings Ltd's Dendrimers Improve Efficacy of Docetaxel in Animals | 02-01-12 |
| European Medicines Evaluation Agency Approves Orphan Medicinal Product Application of Acute Myeloid Leukemia Vaccine | 02-01-12 |
| YOLO Medical Inc. Announces YOLO Curve Receives Health Canada Approval | 02-01-12 |
| Dendreon Corporation Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium | 02-01-12 |
| BioMed Realty and Omeros Corporation Sign New 64,500 Square Foot Lease in Seattle | 02-01-12 |
| Foundation Medicine ReceivesCenters for Medicare & Medicaid Services Certification for its Genomic Sequencing Laboratory | 02-01-12 |
| cGMP CMO Announces EU Compliant Aseptic Fill-Finish and Facility Enhancements for Biopharmaceutical Drug Products | 02-01-12 |
| Almac Group Announce Launch of Next Generation Sequencing (NGS) Data Analysis Services | 02-01-12 |
| Illumina, Inc. Comments on Roche??'s Director Nominees and Proposals | 02-01-12 |
| ImmunoCellular Therapeutics, Ltd Receives Notice of Allowance of Cancer Stem Cell Targeting Patent | 02-01-12 |
| Cook Medical Launches Zenith?? Low Profile Endovascular Graft in Canada | 02-01-12 |
| D&R Acquires LATHIAN to Create Leading Multichannel Marketing Agency | 02-01-12 |
| MEDIAN Technologies has Signed a Landmark Contract with the Top Pharmaceutical Company Sanofi Pasteur for Medical Image Interpretation and Management in a New Phase II Study on Small Cells Lung Cancer | 02-01-12 |
| Pfizer Inc., Eli Lilly and Company Profits Fall as Drugs Lose Patents
| 02-01-12 |
| AcelRx Pharmaceuticals Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012 | 01-31-12 |
| Mesoblast Limited Receives FDA Clearance for Phase 2 Clinical Trial of Proprietary Stem Cell Therapy in Type 2 Diabetes | 01-31-12 |
| McKesson Corporation to Acquire Independent Banner and Franchise Businesses of
| 01-31-12 |
| New Clinical Data for Symphony Presented in Late Breaking Clinical Trials Session at the Annual Meeting | 01-31-12 |
| NanoViricides, Inc. Submits Pre-IND Briefing Document for its Anti-Influenza Drug, FluCide???, to the US FDA
| 01-31-12 |
| MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) and Initiate Phase II RECOVER-ERC Heart Failure Trial | 01-31-12 |
| Alkermes plc Initiates Open-Label Pilot Study of VIVITROL?? to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence | 01-31-12 |
| Lannett Company, Inc. Receives FDA Approval for ANDA Supplement for Phentermine HCL Capsules, 15 mg | 01-31-12 |
| NPS Pharmaceuticals, Inc. Announces FDA Acceptance of New Drug Application for GATTEX?? (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS) | 01-31-12 |
| Daiichi Sankyo, Inc. Logs Loss | 01-31-12 |
| Curis, Inc. Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma | 01-30-12 |
| Vical Incorporated Presents Case Study on Successful Design of Allovectin(R) Phase 3 Melanoma Trial | 01-30-12 |
| ZIOPHARM Oncology, Inc. Announces Recommendation by Independent Data Monitoring Committee to Continue Phase 3 Study of Palifosfamide in Metastatic Soft Tissue Sarcoma | 01-30-12 |
| Cell Therapeutics, Inc. Withdraws New Drug Application for Pixuvri(TM) and Plans to Resubmit in 2012 | 01-30-12 |
| FDA Approves Pfizer Inc.'s INLYTA?? (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC) | 01-30-12 |
| Advanced Cell Technology Announces Aberdeen University Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration | 01-30-12 |
| ISTA Pharmaceuticals, Inc. Completes Patient Enrollment in Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis | 01-30-12 |
| Allos Therapeutics, Inc. Announces Interim Results from Phase 1 Combination Study of FOLOTYN?? and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma | 01-30-12 |
| AMAG Pharmaceuticals, Inc. Announces Completion of Enrollment in its Phase III Program Evaluating Feraheme for a Broader Iron Deficiency Anemia Indication | 01-30-12 |
| KineMed, Inc. Announces Research Collaboration with Pfizer Inc. for the Advancement of Novel Approaches in Metabolic Disease | 01-30-12 |
| Lannett Company, Inc. Receives FDA Approval for Hydrochlorothiazide Capsules, 12.5 mg | 01-30-12 |
| GlaxoSmithKline Seeking Acquisition in Turkey | 01-30-12 |
| GenVec Inc. Extends Research Collaboration with Global Pharmaceutical | 01-27-12 |
| Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrix for U.S. Co-Promotion of GRANISOL(R) (Granisetron) Oral Solution and AQUORAL(TM) Spray and Purchase of Non-U.S. Rights to GRANISOL(R) | 01-27-12 |
| Ipsen Acknowledges Tanakan?? Delisting in France
| 01-27-12 |
| Cornerstone Therapeutics Inc. Release: New Analysis Shows Lower Mortality Rates and Less Need for Redosing When Treating Neonatal Respiratory Distress Syndrome With CUROSURF(R) vs. Survanta(R) | 01-27-12 |
| Celgene Acquisition of Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy | 01-27-12 |
| Lpath, Inc. Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source | 01-27-12 |
| Independent Data Published on BioLife Solutions, Inc. HypoThermosol?? and CryoStor?? | 01-27-12 |
| Infinity Pharmaceuticals Inc. Halts Phase II Cancer Drug Trial, Shares Fall -3.87(38.90%) @ 12:55PM EST | 01-27-12 |
| Cytokinetics, Inc. to Announce Fourth Quarter and Year End Results on February 2, 2012 | 01-27-12 |
| Johnson & Weaver, LLP Announces Investigation in Connection with the Possible Acquisition of Illumina, Inc. by Roche
| 01-27-12 |
| Advaxis, Inc. CEO Interviewed by OneMedPlace Regarding Preliminary Data | 01-27-12 |
| Incyte Corporation to Report Fourth Quarter/Year-End 2011 Financial Results on February 15 | 01-27-12 |
| World-Renowned Cell-Therapy Researcher, Joins Texas Heart Institute at | 01-27-12 |
| Alkermes plc to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012 | 01-27-12 |
| Gilead Sciences, Inc. to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012 | 01-27-12 |
| Roche Responds to Adoption of Shareholder Rights Plan by Illumina, Inc. Board of Directors | 01-27-12 |
| Spectrum Pharmaceuticals, Inc. Strengthens Commercial Operations | 01-27-12 |
| Seattle Genetics, Inc. Announces Data from ADCETRIS??? in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | 01-27-12 |
| Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Report Data from Phase I Trial of ADCETRIS??? in Front-line Mature T-Cell Lymphomas | 01-27-12 |
| Watson Pharmaceuticals, Inc. Reaches Settlement With Mallinckrodt Inc. Over Exalgo(R) | 01-27-12 |
| Pfizer Inc. Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia | 01-27-12 |
| Biogen, Inc., and Elan Corporation PLC Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI?? (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis | 01-26-12 |
| Vanda Pharmaceuticals, Inc. Release: Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder | 01-26-12 |
| Green Cross Gains Market Approval With the World's 2nd Orphan Drug for Hunter Syndrome in South Korea | 01-26-12 |
| Elite Pharmaceuticals, Inc. Announces FDA Approval of Supplemental Application for Hydromorphone | 01-26-12 |
| IntelliCell BioSciences Filed Patent Application for its Proprietary Method of Manufacturing Stromal Vascular Fraction Cells | 01-26-12 |
| Celator Pharmaceuticals, Inc. Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia | 01-26-12 |
| Mayo Clinic Release: Combo Treatment Helps Heal Overused, Aching Joints | 01-26-12 |
| Advaxis, Inc. Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer | 01-26-12 |
| REPEAT/Advaxis, Inc. Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
| 01-26-12 |
| Tysabri, Biogen, Inc., and Elan Corporation PLC Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI?? (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis | 01-26-12 |
| Boehringer Ingelheim Corporation Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib* | 01-26-12 |
| Unity Management Group Subsidiary Announces First Contracts of 2012 With Purdue Pharma L.P. and Novartis AG | 01-26-12 |
| CEL-SCI to Raise $5.76 Million in Registered Direct Offering | 01-26-12 |
| Chimerix, Inc. Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients | 01-25-12 |
| Amorcyte Inc., a NeoStem, Inc. Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction | 01-25-12 |
| OctoPlus Announces the Proposal to Appoint to the Supervisory Board | 01-25-12 |
| Depomed, Inc. Announces Initiation of Phase 2 Clinical Study in Parkinson's Disease | 01-25-12 |
| Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Starts Cohort 2 of Its Phase 1b START-FAP Clinical Trial of CEQ508 | 01-25-12 |
| Gilead Sciences, Inc. Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV | 01-25-12 |
| Advanced Cell Technology Announces that Additional Patient with Stargardt??'s Disease Has Undergone Embryonic Stem Cell Transplantation at University of California, Los Angeles (UCLA)??'s Jules Stein Eye Institute | 01-25-12 |
| AnaSpec, Inc. Offers Symmetric & Asymmetric Dimethylated Arginine in Histone Peptides Collection | 01-24-12 |
| Novartis AG Cautious on Outlook as Profit Drops 46% | 01-25-12 |
| Macoven Pharmaceuticals, LLC Named in Suit for Patent Violation and Lanham Act Violation | 01-25-12 |
| Almirall and Galapagos NV Enter Research Alliance for Up to EUR $7.5 Million | 01-25-12 |
| UCB, Inc. Announces FDA Approval for Keppra?? in Infants and Children from One Month of Age with Partial Onset Seizures | 01-25-12 |
| Merck & Co., Inc.'s Cholesterol Drug Vytorin to Get New Label | 01-25-12 |
| Aptalis Pharmaceutical Technologies Announces FDA Approval of NDA for Oral Powder Formulation of Viread(R), Co-Developed with Gilead Sciences, Inc. | 01-24-12 |
| Boston Therapeutics, Inc. Announces Clinical Study Safety Results With SUGARDOWN(R) at University of Sydney | 01-24-12 |
| Advanced Cell Technology Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients | 01-24-12 |
| Roche Release: HPV Testing for Cervical Cancer Risk Patients Set to Increase | 01-24-12 |
| Van Andel Institute Study Provides New Details of Fundamental Cellular Process | 01-24-12 |
| ImmunoCellular Therapeutics, Ltd: Targeting Cancer Stem Cells | 01-24-12 |
| Appistry, Inc. Establishes Genomic Research Collaboration with University of Missouri
| 01-24-12 |
| Santhera Pharmaceuticals AG and Ipsen Renegotiate Fipamezole Licensing Agreement | 01-24-12 |
| BioLineRx Ltd. Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C | 01-24-12 |
| IMS Health Acquires in India, Strengthening Global Services Capabilities | 01-24-12 |
| LAB21 Limited Acquires New Real Time PCR Technology | 01-24-12 |
| MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) and Licensee ERCell Receive Russian Regulatory Approval for the RECOVER-ERC Trial | 01-24-12 |
| Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori Therapeutics, Inc.'s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function | 01-24-12 |
| POET Gets New Partner in $250 Million Cellulosic Ethanol Plant in Iowa | 01-24-12 |
| immatics biotechnologies GmbH Presents Positive Phase II Results With its Therapeutic Cancer Vaccine IMA910 in Patients With Advanced Colorectal Cancer at the 2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | 01-24-12 |
| Roche Settles Claims Over Genentech's Raptiva Psoriasis Drug, Lawyer Says | 01-24-12 |
| B.Braun Medical Becomes the First to Deliver FDA-Approved 2g Cefazolin | 01-23-12 |
| Enlivex Therapeutics Ltd. Completes Patient Enrollment in its Phase I/II Clinical Trial | 01-23-12 |
| NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422 | 01-23-12 |
| Carolus Therapeutics Reports Publication of Preclinical Data for CT-2009 Supporting Development in Acute Lung Injury | 01-23-12 |
| Infinity Pharmaceuticals Inc. Reports New Data from Phase 1b Trial of Saridegib in Patients with Pancreatic Cancer at | 01-23-12 |
| Advanced Cell Technology Announces Europe??'s First Human Embryonic Stem Cell Transplant in Patient with Stargardt??'s Disease | 01-23-12 |
| Active Biotech AB's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial | 01-23-12 |
| EpiCept Corporation Receives Finalized FDA Guidance for AmiKet??? Phase III CIPN Program and Regulatory Strategy | 01-23-12 |
| ImmunoCellular Therapeutics, Ltd Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma | 01-23-12 |
| Trius Therapeutics Earns $5 Million Milestone Payment From Bayer HealthCare for Successful Completion of First Phase 3 Trial of Tedizolid | 01-23-12 |
| Exelixis, Inc. Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients With Hepatocellular Carcinoma | 01-23-12 |
| Chikujee Therapeutics, Inc. and Avanti Therapeutics Achieve Key Pre-Clinical Milestone in Ovarian Cancer Program | 01-20-12 |
| Mylan Inc. Launches Innovative Version of Antiepileptic Drug Levetiracetam | 01-20-12 |
| Jiangsu Kanion Out-licenses 3 Molecules to NewGen Therapeutics | 01-20-12 |
| PolyMedix Inc. Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria | 01-20-12 |
| Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology??'s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to | 01-20-12 |
| Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence | 01-20-12 |
| Cubist Pharmaceuticals, Inc. Reports 2011 Fourth Quarter and Full Year Financial Results | 01-20-12 |
| Rainbow Coral Corp. Release: Rainbow BioSciences, LLC Targets Booming Diabetes Research Market | 01-20-12 |
| Thermo Fisher Scientific Expands Its Popular Microdialysis Product Line | 01-20-12 |
| Bioindustry Support Solutions, LLC Release: STATKING Consulting, Inc. Signs Agreement to Provide Webinar Content | 01-20-12 |
| Data on Navidea Biopharmaceuticals??'s AZD4694 Presented by the Banner Alzheimer's Institute at the 6th Annual Human Amyloid Imaging Meeting (HAI) | 01-20-12 |
| PolyTherics Acquires and Expands Technology Portfolio to Enable the Development of Better Biopharmaceuticals | 01-20-12 |
| Genzyme Corporation and Veracyte, Inc. Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients | 01-20-12 |
| Avila Therapeutics Announces FDA Allowance of PartnerClovis Oncology??'s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor | 01-20-12 |
| Idera Pharmaceuticals, Inc. Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva?? and Avastin?? in Patients with Advanced Non-Small Cell Lung Cancer | 01-20-12 |
| Nordion International Enters Six-Year Cobalt-60 Supply Agreement with | 01-19-12 |
| ShangPharma Announces Milestone Achievement in Research Partnership with | 01-19-12 |
| ShangPharma Achieves First Milestone in Jiangsu Hengrui Medicine Co. Ltd. Biologics Partnership | 01-19-12 |
| Watson Pharmaceuticals, Inc. Launches Generic Yaz(R) | 01-19-12 |
| Commonwealth Laboratories, Inc. and Health Point Press Announce a New Association Which Will Work to Promote Small Intestinal Bacteria Overgrowth (SIBO) and its Correlation to Irritable Bowel Syndrome (IBS) | 01-19-12 |
| A*STAR, GE Global Research Join Forces to Develop Integrated Advanced Medical Imaging Technologies for Improved Clinical Diagnosis | 01-19-12 |
| HUYA Bioscience International Announces Strategic Partnership with the | 01-19-12 |
| Elsevier, Inc. and Tsinghua University Department of Computer Science and Technology Create New Research Productivity Solutions | 01-19-12 |
| Sabin Vaccine Institute Release: Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil | 01-19-12 |
| Adeona Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Trimesta(TM) for Cognitive Dysfunction in Multiple Sclerosis | 01-19-12 |
| Eisai Company, Ltd. Receives Approval to Market Insomnia Treatment Lunesta in Japan | 01-19-12 |
| Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions | 01-19-12 |
| Apricus Biosciences Retains as Investor Relations Firm | 01-19-12 |
| Complete Genomics, Inc. Publishes Paper Describing Its Informatics Approach for High-Accuracy Whole Human Genome Sequencing | 01-19-12 |
| Genta Incorporated Release: New Clinical Trial Confirms the Activity of Tesetaxel in Patients With Advanced Gastric Cancer | 01-19-12 |
| Roy D. Baynes, MD, PhD, to Join Gilead Sciences Ltd. as Senior Vice President, Oncology Therapeutics Network | 01-19-12 |
| Nancy Hutson Appointed toBiocryst Pharmaceuticals??'s Board of Directors | 01-19-12 |
| Precision BioSciences Announces Establishment of for Development of Advanced Agricultural Biotechnology | 01-19-12 |
| Biovest International, Inc. Prepares for EU Regulatory Meetings; SME Status Granted Providing European Regulatory Benefits for BiovaxID Personalized Lymphoma Vaccine | 01-19-12 |
| Ono Pharmaceutical Company, Ltd. Selects Medidata Rave as Enterprise EDC/CDM Solution | 01-19-12 |
| NovaDel Pharma Continuing to Explore Strategic Alternatives | 01-19-12 |
| Vitae Pharmaceuticals, Inc. Secures $15 Million Senior Credit Facility | 01-19-12 |
| Mayo Clinic Release: New Test Offers Greater Accuracy in Early Detection of Colorectal Cancer | 01-19-12 |
| Johannes Gutenberg University Release: First Preclinical Proof-of-Concept of Mutation-Based Individualized Cancer Vaccine | 01-18-12 |
| The Medicines Company's Cangrelor Bridge Trial Published in the JAMA | 01-18-12 |
| Immunomedics, Inc. Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection | 01-18-12 |
| Teijin Pharma's Bonalon Bag for I.V. Infusion 900 ??g Approved as Japan's First I.V. Drug for Osteoporosis | 01-18-12 |
| Quintiles, Inc. Takes Stake in UK Biomarker Startup | 01-18-12 |
| Courtagen Life Sciences Acquires Medicinal Genomics | 01-18-12 |
| inVentiv Health Release: IMS Health Signs Agreement to Divest SDI Medical and Promotional Audits | 01-18-12 |
| Rexahn Pharmaceuticals, Inc. Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors
| 01-18-12 |
| Gilead Sciences Ltd. Completes Acquisition of Pharmasset, Inc. | 01-18-12 |
| Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel | 01-18-12 |
| Provectus Pharmaceuticals Inc. Receives Guidance From FDA on Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma | 01-18-12 |
| Mayo Clinic Release: Drug Improves Survival of Colorectal Cancer Patients, Trial Results Show | 01-18-12 |
| Jazz Pharmaceuticals, Inc. and Azur Pharma Inc. Combine to Create | 01-18-12 |
| Genzyme Corporation Announces European Approval of Framingham Genomic Medicine Inc. Manufacturing Plant | 01-18-12 |
| Daiichi Sankyo, Inc. Officials to Monitor New Ranbaxy Laboratories Unit | 01-18-12 |
| Xiamen Innovax Biotech Gains Approval for Hepatitis E Vaccine | 01-17-12 |
| Protalex, Inc. Announces Completion of Dosing Patients in 4th Cohort of Its Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis | 01-17-12 |
| Ventrus Biosciences, Inc. Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease | 01-17-12 |
| BrainStorm Cell Therapeutics Inc. Announces Clinical Data Supporting Safety and Efficacy of NurOwn??? Based on Initial Patient Results | 01-17-12 |
| Scil Proteins GmbH to Manufacture Reteplase for Actavis
| 01-17-12 |
| Enzymicals AG and Herbrand PharmaChemicals GmbH Cooperate for Biotechnological Production of Pharmaceuticals and Intermediates | 01-17-12 |
| Celldex Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial of CDX-301 | 01-17-12 |
| InVivo Therapeutics Corporation, Geisinger Health System to Conduct Preclinical Study of Injectable Scaffold for Peripheral Nerve Injury for FDA Submission
| 01-17-12 |
| Da An Gene and Life Technologies Form $5.5 Million JV | 01-17-12 |
| Leading Eye Institute to Participate in Advanced Cell Technology??'s Embryonic Stem Cell Clinical Trial for Macular Degeneration | 01-17-12 |
| Former Sanofi-Aventis K.K. and US Oncology Executive Joins as Chief Executive Officer | 01-17-12 |
| Jiangsu Hengrui Medicine Co. Ltd. and Crown Bioscience, Inc. Announce Antibody Partnership | 01-13-12 |
| Swedish Orphan Biovitrum Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals | 01-13-12 |
| Amerigen Pharmaceuticals Announces Two China-US Deals | 01-13-12 |
| Omni Bio Pharmaceutical to Conduct New Human Clinical Trials | 01-13-12 |
| First FDA-Approved Study of Stem Cells to Treat Hearing Loss Begins at | 01-13-12 |
| Sangart, Inc. Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease | 01-13-12 |
| To Bolster Pipeline, GlaxoSmithKline Exec Scouts Prospects | 01-13-12 |
| NextDocs Selected by AlwaysOn as a Venture Summit Mid-Atlantic 100 Winner | 01-13-12 |
| 9th Annual Biotechnology Industry Organization (BIO) Asia International Conference to Feature New Deal Models and Discuss the Future of Innovation in Asia | 01-13-12 |
| Genentech Announces First Milestone Payment to Device-Maker ForSight Labs, LLC in Development of Sustained Delivery Lucentis | 01-13-12 |
| Amarantus BioSciences, Inc. to be Interviewed on | 01-13-12 |
| Agilux Laboratories Announces Validation and Implementation of Thermo Watson Laboratory Information System | 01-13-12 |
| Metabolix, Inc. Announces Termination of
| 01-13-12 |
| Seattle Genetics, Inc. Announces Updates to ADCETRIS??? Prescribing Information | 01-13-12 |
| Rainbow BioSciences, LLC Enters New World of Opportunity | 01-13-12 |
| Royal DSM is Awarded Membership in the PANOPTES EU Funded Consortium | 01-13-12 |
| Nuron Biotech Licenses HibTITER?? Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market | 01-13-12 |
| Advanced BioNutrition Corporation and Sign Global Agreement | 01-13-12 |
| St. Jude Children's Research Hospital Release: Gene Identified as a New Target for Treatment of Aggressive Childhood Eye Tumor | 01-12-12 |
| Three Adimab LLC. Antibodies Enter Human Clinical Trials | 01-12-12 |
| Merrimack Pharmaceuticals Inc. Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors | 01-12-12 |
| Senova Systems, Inc. Inks $6.7 Million Series B | 01-12-12 |
| Biovest International, Inc. Collaborates with Max Planck Institute to Advance its Hollow Fiber Bioreactors for the Manufacture of Viral Vaccines | 01-12-12 |
| BioReference Laboratories, Inc. Announces Contract with to Provide Correctional Healthcare Laboratory Services | 01-12-12 |
| Genethon, Encouraging Results in a Phase I Clinical Trial in Limb-Girdle Muscular Dystrophy Type 2C | 01-12-12 |
| Perrigo Company Wins Summary Judgment in Generic Mucinex?? Case | 01-12-12 |
| Senova Systems Inks $6.7 Million Series B | 01-12-12 |
| PharMerica Drops on Report its Takeover My be Blocked by U.S. Regulators | 01-12-12 |
| Pfizer Inc. Contraceptive Seized in India for Misbranding | 01-12-12 |
| Cebix Incorporated to Raise $20 Million for Pivotal Trial of Diabetes Supplement | 01-11-12 |
| GE Healthcare to Enhance EP Portfolio of Offerings through Biosense Webster, Inc. Agreement | 01-11-12 |
| China Nuokang Bio-Pharmaceutical Inc. Broadens Product Portfolio by Acquiring Alpha Lipoic Acid Capsule for Diabetic Patients | 01-11-12 |
| Sumagen Initiates Clinical Testing of Omnia Biologics, Inc. Manufactured HIV Vaccine | 01-11-12 |
| Pharmos Corporation Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout | 01-11-12 |
| Vical Incorporated Provides Updates on CMV Vaccine Programs | 01-11-12 |
| Gynecologic Oncology Group and Advaxis, Inc. Release: Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV
| 01-11-12 |
| Starpharma Holdings Ltd Receives FDA Special Protocol Assessment for BV Phase 3 | 01-11-12 |
| FDA Grants Hemispherx Biopharma Extension in Its Pending New Drug Application (NDA) for the Treatment of Chronic Fatigue Syndrome (CFS) | 01-11-12 |
| Actelion Ltd. CEO Says Macitentan Has 'Very High' Chances of Success | 01-11-12 |
| Polaris Goup Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer | 01-10-12 |
| Cubist Pharmaceuticals, Inc. and Hydra Biosciences, Inc. Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain | 01-10-12 |
| Sinovac Biotech Ltd. Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease | 01-10-12 |
| Arena Pharmaceuticals, Inc.: FDA Accepts Resubmission of Lorcaserin New Drug Application | 01-10-12 |
| Telormedix Secures Further Funding With $7.5 Million CHF | 01-10-12 |
| University of California, San Francisco (UCSF), Sanofi (France) Collaborate to Find New Diabetes Cures | 01-10-12 |
| Dako A/S and Amgen to Collaborate in Development of a Companion Diagnostic for an Investigational Cancer Therapy | 01-10-12 |
| National Institute for Clinical Excellence (NICE) Seeks More Info on Bayer HealthCare's Xarelto | 01-10-12 |
| Genome Institute of Singapore Scientists Identify Lung Cancer Stem Cells and New Drug Targets | 01-06-12 |
| Jazz Pharmaceuticals, Inc. Provides Financial Outlook for 2012 | 01-06-12 |
| Cancer Researcher at Develops Nontoxic Compounds | 01-06-12 |
| Goff Hill Ltd. Announces the Cure for Cancer and Viral Diseases | 01-06-12 |
| Novel Brain Tumor Vaccine Acts Like Bloodhound to Locate Cancer Cells, Wake Forest University Baptist Medical Center Study | 01-06-12 |
| Pharming Group Redeems Part of Convertible Bond | 01-06-12 |
| CoDa Therapeutics, Inc., Mesynthes, and Pacific Edge Biotechnology Ltd. (PEB), Release:Showcased to Health Care Investment and Partnering Community | 01-06-12 |
| University of California, San Francisco (UCSF) Files Appeal of Judgment in Favor of InSite Vision | 01-06-12 |
| ISTA Pharmaceuticals, Inc. Announces U.S. Patent Allowance for PROLENSA(TM) in the United States | 01-06-12 |
| KAI Pharmaceuticals, Inc. Announces Initiation of Second Phase 2 Study of KAI-4169 | 01-06-12 |
| Covidien Completes Acquisition of BARRX Medical, Inc.
| 01-06-12 |
| Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson's Disease | 01-06-12 |
| Alnylam Pharmaceuticals Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis | 01-06-12 |
| Amicus Therapeutics, Inc. Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease | 01-06-12 |
| Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Closes Previously Announced $5 Million Financing | 01-06-12 |
| Analysts: Amgen, Celgene Need to Make Acquisitions to Boost Growth | 01-06-12 |
| Pharma Firm Norgine Plans 36 Job Losses | 01-06-12 |
| DURECT Corporation's Phase III Study Did Not Show Significant Results for Posidur | 01-06-12 |
| Pfizer Inc. Restructures Indian Animal-Health Unit to Prepare for Consolidation | 01-06-12 |
| Johnson & Johnson to Pay $1 Billion to Settle Risperdal Marketing Probe | 01-06-12 |
| Biotech Firm Cangene Corporation Cuts 120 Jobs | 01-06-12 |
| Endo Pharmaceuticals to Pay Up to $180 Million Plus Royalties to BioDelivery Sciences International in Drug Pact; Stock Rises +0.97(115.46%) @ 10:12AM EST | 01-06-12 |
| Neovacs SA Major Milestone Achieved: The Phase IIa Clinical Trial in Rheumatoid Arthritis Meets Its Endpoint | 01-05-12 |
| ThermoGenesis Announces Approval of AXP(R) by | 01-05-12 |
| Apogenix Raises ???7.5 Million to Further Advance APG101 to Treat Glioblastoma and Other Tumors | 01-05-12 |
| Kraig Biocraft Laboratories, Inc. Announces Peer Reviewed Publication of Spider Silk and Transgenic Silkworm Breakthroughs | 01-05-12 |
| Tetragenetics, Inc.??? G-SOME???-Formulated Influenza Vaccine Provides Strong Protection Against H5N1 in Preclinical Efficacy Study | 01-05-12 |
| Ritter Pharmaceuticals, Inc.' RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial | 01-05-12 |
| ISTA Pharmaceuticals, Inc. Initiates Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis | 01-05-12 |
| Basilea Pharmaceutica to File Application for Marketing Authorization of Ceftobiprole for the Treatment of Pneumonia | 01-05-12 |
| Alnylam Pharmaceuticals and Arrowhead Research Corporation Form Collaboration and Licensing Agreement | 01-05-12 |
| Senesco Technologies, Inc. and Enter into New Agreement | 01-05-12 |
| Ensemble Therapeutics Corporation Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb Company | 01-05-12 |
| Vitae Pharmaceuticals, Inc. to Present at the 30th Annual Healthcare Conference | 01-05-12 |
| Ironwood Pharmaceuticals and Bionomics Limited Announce Collaboration, Research, and License Agreement | 01-05-12 |
| Oncodesign SA and Ipsen Enter into a Research Collaboration for the Development of New Therapeutic Agents against the LRRK2 Parkinson's disease Target | 01-05-12 |
| Baxter International, Inc. Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A | 01-05-12 |
| ProFibrix US Phase II Study with Meets All Primary and Secondary Endpoints | 01-05-12 |
| RegeneRx Biopharmaceuticals, Inc. Receives Clinical Study Report for Phase 2 Dry Eye Trial | 01-05-12 |
| Repros Therapeutics Inc. Completes Dosing in Phase 2 Low-Dose Oral Proellex(R) Trial | 01-04-12 |
| PolyMedix Inc. Completes Enrollment in Phase 2 Trial With PMX-30063 Defensin-Mimetic Antibiotic | 01-04-12 |
| Achillion Pharmaceuticals, Inc. Release: ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C | 01-04-12 |
| Veloxis Pharmaceuticals A/S Announces Initiation of STRATO Study of LCP-Tacro(TM) in Kidney Transplant Recipients Experiencing Tremors | 01-04-12 |
| Arrowhead Research Corporation Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial | 01-04-12 |
| First Human Volunteer Immunized in Clinical Trial of Profectus BioSciences, Inc.??? Vesicular Stomatitis Virus-vectored HIV-1 Vaccine | 01-04-12 |
| AVI BioPharma, Inc. Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial | 01-04-12 |
| Celldex Therapeutics, Inc. Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin?? Naive and Refractory Populations | 01-04-12 |
| Alnylam Pharmaceuticals Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia | 01-04-12 |
| Alkermes plc Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder | 01-04-12 |
| Eppendorf AG Licenses Technology for Thermal Cyclers to | 01-03-12 |
| BioMarin Pharmaceutical Inc. Announces IND for BMN-111 for Achondroplasia is Active | 01-03-12 |
| Chelsea Therapeutics, Inc. Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH | 01-03-12 |
| FDA's Oncologic Drugs Advisory Committee to Review Cell Therapeutics, Inc.'s Resubmitted Pixantrone New Drug Application on February 9, 2012 | 01-03-12 |
| XOMA (US) LLC Secures $10 Million Term Loan | 01-03-12 |
| Amgen Release: FDA to Review Potential New Use of XGEVA(R) (Denosumab) at Oncologic Drugs Advisory Committee Meeting | 01-03-12 |
| Agile Therapeutics, Inc. Announces Completion of AG200-15 Phase III Clinical Program | 01-03-12 |
| Osiris Therapeutics, Inc. Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes | 01-03-12 |
| XOMA Ltd. Secures $10 Million Term Loan | 01-03-12 |
| Astex Pharmaceuticals Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML
| 01-03-12 |
| Harbin Pharmaceutical Group Holding Co., Ltd. Trades $870 Million of Stock for Assets from Parent | 01-03-12 |
| Van Andel Institute Findings Provide More Complete Understanding of Kidney Cancer | 12-29-11 |
| Alexion Pharmaceuticals Inc. to Host Conference Call This Morning to Discuss Company??'s Proposed Acquisition of Enobia Pharma | 12-29-11 |
| Marshall Edwards, Inc. Adds $2 Million in Private Placement | 12-29-11 |
| Opko Health, Inc. Completes Acquisition of FineTech Pharmaceutical, Ltd.
| 12-29-11 |
| Roche's Avastin Disappoints Against Ovarian Cancer | 12-29-11 |
| China Sky One Medical, Inc. Announces Resignation of its Chief Financial Officer | 12-29-11 |
| SBS Group Selected as 2011 VAR Star | 12-29-11 |
| Biogen, Inc. to Present at the Goldman, Sachs & Co. Healthcare CEOs Unscripted Conference | 12-29-11 |
| Peregrine Pharmaceuticals, Inc. Provides Update on HCV Clinical Program | 12-29-11 |
| RTI Biologics Achieves 98.7 Percent Equipment Performance Rating ??? Recognized in
| 12-29-11 |
| Foundation Fighting Blindness Announces $1.8 Million Grant to Leading Netherlands Institute, Expands International Research Portfolio | 12-29-11 |
| Alexion Pharmaceuticals Inc. to Host Conference Call This Morning to Discuss Company??'s Proposed Acquisition of Enobia Pharma
| 12-29-11 |
| AAIPharma Services Achieves Record Quarterly Results | 12-29-11 |
| IGI Laboratories, Inc. Announces the Submission of Fifth ANDA | 12-29-11 |
| Opko Health, Inc. Completes Acquisition of
| 12-29-11 |
| FDA Accepts New Drug Application for Gilead Sciences, Inc.??'s Once-Daily, Single-Tablet Quad HIV Regimen | 12-28-11 |
| United Therapeutics Corporation Release: Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union | 12-28-11 |
| IntelGenx Corp. Announces Health Canada Approval for Anti-Migraine VersaFilm Pivotal Clinical Trial | 12-28-11 |
| ThromboGenics NV Submits Biologics License Application for Ocriplasmin to the U.S. FDA | 12-28-11 |
| VIVUS, Inc. Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity | 12-28-11 |
| Protox Therapeutics Inc. Announces Closing of Additional CDN $8.3 Million Investment by Warburg, Pincus Ventures, L.P. | 12-28-11 |
| Beijing Double-Crane Pharmaceutical Co., Ltd. Buys Transfusion Maker for $17.4 Million | 12-28-11 |
| Albany Molecular Research, Inc. (AMRI) Cuts Jobs in Q4 | 12-28-11 |
| 22nd Century Group, Inc. Announces Initial Results of Smoking Cessation Trial | 12-28-11 |
| Emergent BioSolutions Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia | 12-28-11 |
| Bristol-Myers Squibb Company Release: BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed | 12-28-11 |
| EpiCept Corporation Receives FDA Permission to Initiate AmiKet??? Phase III Clinical Development | 12-28-11 |
| Noven Pharmaceuticals Inc. Announces Phase 3 Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms | 12-28-11 |
| CEL-SCI Announces Fiscal 2011 Financial Results | 12-28-11 |
| Anacor Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase 3 Trials of Tavaborole for Onychomycosis | 12-28-11 |
| FDA Accepts New Drug Application for Gilead Sciences Ltd.??'s Once-Daily, Single-Tablet Quad HIV Regimen | 12-28-11 |
| Perrigo Company Announces FDA Final Approval for Desloratadine | 12-28-11 |
| Fero Industries, Inc. Signs New Distribution Agreement to Expand Sucanon(R) Presence in the Middle East | 12-22-11 |
| New CEO Appointed Head of | 12-22-11 |
| Ventrus Biosciences, Inc. Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures | 12-22-11 |
| Eisai Company, Ltd. Submits Application for Partial Change to Label of Egg White Lysozyme Preparation Neuzym | 12-22-11 |
| Tekmira Pharmaceuticals Corporation Secures $3 Million Financing | 12-22-11 |
| CytRx Corporation Initiates International Phase 2b Clinical Trial with INNO-206 in Advanced Soft Tissue Sarcoma | 12-22-11 |
| AVEO Pharmaceuticals, Inc. Announces Patient Enrollment in Phase 2 Clinical Trial of Tivozanib in Combination with mFOLFOX6 in Patients with Advanced Colorectal Cancer | 12-22-11 |
| Curis, Inc. Announces Collaborator Roche??'s Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma | 12-22-11 |
| IMPAX Laboratories, Inc. Asks FDA for Approval of Parkinson's Drug | 12-22-11 |
| New C.E.O. Appointed Head of | 12-22-11 |
| Chelsea Therapeutics, Inc. Reports Topline Results From Phase II Trial of Droxidopa in Fibromyalgia | 12-22-11 |
| Pfizer Inc. Reports Results From Three Phase 4 Studies Demonstrating EMBEDA?? (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact on Drug Liking and Withdrawal Symptoms | 12-22-11 |
| Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson??'s Disease
| 12-21-11 |
| Raptor Pharmaceutical Inc. Provides Program Update on RP103 (DR Cysteamine) for Nephropathic Cystinosis | 12-21-11 |
| OphthaliX Inc. Release: Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study | 12-21-11 |
| Santarus Inc. Submits New Drug Application to FDA for UCERIS (budesonide) Tablets | 12-21-11 |
| BioTie Therapies Corp.'s Partner Lundbeck Inc. Submits European Marketing Authorization Application for Selincro(TM) (nalmefene) | 12-21-11 |
| Salix Pharmaceuticals, Ltd. Completes Acquisition of Oceana Therapeutics
| 12-21-11 |
| Celldex Therapeutics, Inc. Completes Accrual of CDX-011 Phase 2b ???EMERGE??? Study in Advanced Breast Cancer
| 12-21-11 |
| Santarus Inc. Submits New Drug Application to FDA for UCERIS (budesonide) Tablets
| 12-21-11 |
| Repligen Corporation Announces Submission of New Drug Application for SecreFlo??? for Improved Pancreatic Imaging In Patients with Pancreatitis | 12-21-11 |
| Gilead Sciences, Inc. Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection | 12-21-11 |
| Phage Pharmaceuticals (Formerly Known as Phage Biotechnology Corp.) to File Investigational New Drug (IND) Application Using Its Lead Drug Candidate, FGF-1, for a First-in-Class Indication to Repair Tympanic Membrane Perforations | 12-21-11 |
| Zogenix, Inc. Completes Zohydro(TM) Pre-NDA Meetings With FDA | 12-20-11 |
| Zogenix, Inc. and Astellas Pharma US Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective March 31, 2012 | 12-21-11 |
| Record Breaking $327 Million Verdict Upheld in Janssen Pharmaceutical K.K. Case and Request for New Trial Denied | 12-21-11 |
| Antares Pharma, Inc. Enters Licensing Agreement with Pfizer Consumer Healthcare | 12-20-11 |
| MacroGenics, Inc. Receives Milestone Payment as Part of Its Global DART??? Alliance With Boehringer Ingelheim Corporation
| 12-20-11 |
| Hua Medicine Licenses Novel Drug Candidate From Roche for Potential Treatment of Diabetes | 12-20-11 |
| Orexo AB: Positive Study Results for OX27 | 12-20-11 |
| Provectus Pharmaceuticals Inc. and its Subsidiaries Complete Unregistered Offering of Units to Facilitate Spin-off of | 12-20-11 |
| DARA BioSciences, Inc. Reports Appointment of as a Director and Designation of as President and Chief Executive Officer | 12-20-11 |
| ProteoTech Announces Drug Development Collaborative Agreement with GlaxoSmithKline for New Parkinson's Therapeutic | 12-20-11 |
| China Sky One Medical, Inc.'s Chief Executive Officer to Take Sick Leave | 12-20-11 |
| Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide | 12-19-11 |
| Raptor Pharmaceutical Inc. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis ("NASH") | 12-19-11 |
| Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL(TM) Pivotal Trial Published in Diseases of the Colon & Rectum | 12-19-11 |
| Amicus Therapeutics, Inc. Completes Enrollment of 67 Patients in Phase 3 Study of Migalastat HCl for Fabry Disease | 12-19-11 |
| Planning for Patrys Limited' Multiple Myeloma Trial Underway | 12-19-11 |
| Ardea Biosciences, Inc. Initiates Phase 3 Clinical Development Program for Lesinurad | 12-19-11 |
| Zalicus Inc. Initiates Phase 1 Clinical Trial of Z944 | 12-19-11 |
| Alkermes plc Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia | 12-19-11 |
| AbGenomics Corporation Regains Global Rights to AbGn-168H from Boehringer Ingelheim Corporation | 12-19-11 |
| AmerisourceBergen Corporation Release: US Bioservices Corporation Receives Accreditation | 12-19-11 |
| Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceutical, Co., Ltd, in United States and European Union Territories | 12-19-11 |
| Galapagos NV Achieves Clinical Proof-of-Mechanism Milestone in GlaxoSmithKline Alliance
| 12-19-11 |
| VHGI Holdings, Inc. Announces Intent to Spin-Out Medical Office Software Subsidiary | 12-19-11 |
| AstraZeneca PLC's Brilique is First Drug to Gain Post-AMNOG Decision in Germany | 12-19-11 |
| Alexza Pharmaceuticals, Inc. Explores Sale, Warns of Job Cuts | 12-19-11 |
| ChromaDex, Inc. Announces Successful Completion of Patient Enrollment for the First Human Clinical Study of its Proprietary pTeroPure(R) | 12-16-11 |
| NeurogesX, Inc. Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN) | 12-16-11 |
| Valeant Pharmaceuticals International Launches $327 Million Hostile Bid for ISTA Pharmaceuticals, Inc., Rejects Offer | 12-16-11 |
| AHF Slams Gilead Sciences Ltd. ???HIV Prevention Pill??? FDA Application | 12-16-11 |
| Company Profile for
| 12-16-11 |
| Landmark Publication Endorses PRANA Biotechnology's Drug Pipeline Strategy for Treating Neurodegenerative Diseases | 12-16-11 |
| BioTime??'s Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM | 12-16-11 |
| Seventh Sense Biosystems Inc. Receives $3.28 Million Grand Challenges Grant to Expand Touch Activated Phlebotomy??? Technology Platform | 12-16-11 |
| Laboratory Corporation of America Holdings (LabCorp) Successfully Completes Acquisition of Orchid Cellmark
| 12-16-11 |
| Omnicare, Inc. Files Amendment to Tender Offer to Acquire PharMerica | 12-16-11 |
| Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at | 12-16-11 |
| FDA Approves Baxter International, Inc.??'s ADVATE as the Only FVIII for Routine Prophylaxis in Both Adults and Children with Hemophilia A | 12-16-11 |
| ThromboGenics Ltd. and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule | 12-16-11 |
| Advaxis, Inc. Reports Preliminary Data from ADXS-HPV Phase 2 Trial in Patients with Recurrent/Refractory Cervical Cancer at | 12-16-11 |
| Radius Takes Final Bite of its $91 Million Financing Apple | 12-16-11 |
| #1 Branded Topical Acne Product, Epiduo(R) Gel of Galderma Laboratories, Receives FDA Approval for a New Convenient Pump Dispenser Third Rock Ventures | 12-15-11 |
| Isis Pharmaceuticals, Inc. Updates KYNAMRO Submission Timeline | 12-15-11 |
| Vertex Pharmaceuticals Incorporated Release: FDA Grants Priority Review for KALYDECO??? (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis | 12-15-11 |
| Repros Therapeutics Inc. Meets With the Divisions of Urologic and Endocrinologic Products at FDA to Plan Direction of Phase 3 Program for Androxal(R) | 12-15-11 |
| #1 Branded Topical Acne Product, Epiduo(R) Gel of Galderma Laboratories, Receives FDA Approval for a New Convenient Pump Dispenser | 12-15-11 |
| Emisphere Technologies, Inc. Reports Update on the Clinical Development of Oral Calcitonin in Osteoarthritis and Osteoporosis | 12-15-11 |
| Eisai Company, Ltd. Announces Canadian Approval of its Anticancer Agent Halaven | 12-15-11 |
| ViroPharma Incorporated Announces Approval of Modernized Labeling for Vancocin(R) (Vancomycin Hydrochloride, USP) Capsules | 12-15-11 |
| PRANA Biotechnology Commences Alzheimer's Trial Recruitment | 12-15-11 |
| REGENX BioSciences Highlights Gene Therapy Advances in the Prevention and Treatment of HIV and Hemophilia B Using NAV(TM) rAAV8 Vectors | 12-15-11 |
| FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept Therapeutics Inc.'s Proposed Distribution of Korlym(TM) for Cushing's Syndrome | 12-15-11 |
| AvidBiotics Release: DGR Technology Platform for Engineering Proteins Advanced in Publication by Collaborators
| 12-15-11 |
| Sartorius AG Closes Acquisition of the Biohit Liquid Handling Business | 12-15-11 |
| Cancer Prevention Coalition: Multiple Carcinogens in Johnson & Johnson??'s Baby Shampoo | 12-15-11 |
| NuGEN Technologies, Inc. Sample Preparation Solutions Selected by Rutgers University Cell and DNA Repository for Large Scale Alcoholism Study | 12-15-11 |
| Human Genome Sciences, Inc. and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA??) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus
| 12-15-11 |
| BioSante Pharmaceuticals, Inc. Announces Results from LibiGel?? Efficacy Trials | 12-15-11 |
| Rib-X Pharmaceuticals, Inc. Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections | 12-15-11 |
| FDA Grants Priority Review for KALYDECO??? (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis | 12-15-11 |
| Meta-analysis of Five Clinical Trials Including Columbia Laboratories, Inc.??? PREGNANT Study Published in
| 12-14-11 |
| Salix Pharmaceuticals, Ltd. Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
| 12-14-11 |
| Merrimack Pharmaceuticals Inc. Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers | 12-14-11 |
| Pharmacyclics, Inc. Announces Updated Results for BTK Inhibitor PCI-32765 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma at American Society of Hematology (ASH) Annual Meeting | 12-14-11 |
| Celgene International S??rl Release: Phase III Study Evaluating REVLIMID?? in Patients with High-Risk Smoldering Multiple Myeloma Presented at
| 12-14-11 |
| Quintiles, Inc. Launches China CRO,
| 12-14-11 |
| Johnson & Johnson Appoints New Chief of Marketing, PR After Recalls | 12-14-11 |
| Linguamatics Ltd and ChemAxon Ltd. Announce Project to Enhance Text Mining in Chemistry | 12-14-11 |
| NeurOp Corporation Announces Extension to Drug Discovery Collaboration with Bristol-Myers Squibb Company | 12-14-11 |
| Mayo Clinic Release: Scientists Develop Vaccine That Successfully Attacks Breast Cancer in Mice
| 12-14-11 |
| Celgene International S??rl Release: in Adult Lymphoma Research (GELA) Chooses REVLIMID?? for Study in Second Most Common Lymphoma Subtype | 12-14-11 |
| Idera Pharmaceuticals, Inc. Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8, at the American Society of Hematology | 12-14-11 |
| Celgene International S??rl Release: Final Phase II Data Evaluating REVLIMID?? and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia | 12-14-11 |
| Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate?? (Romiplostim)
| 12-14-11 |
| Threshold Pharmaceuticals, Inc. Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias | 12-14-11 |
| Celgene International S??rl Release: Phase III Study Evaluating REVLIMID?? in Patients with High-Risk Smoldering Multiple Myeloma Presented at Celgene International S??rl
| 12-14-11 |
| Salix Pharmaceuticals, Ltd. Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
| 12-14-11 |
| The Best Biotech CEO of 2011 Is... | 12-14-11 |
| Celgene International S??rl Release: Phase III Study with REVLIMID?? Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma | 12-13-11 |
| PCI Synthesis Completes R&D Expansion of 30%, Adds 20 New Hires & Signs Agreement With Biogen Idec, Inc. (Massachusetts) | 12-13-11 |
| Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA(TM) Oral Calcitonin | 12-13-11 |
| Eisai Company, Ltd. Submits Application in Japan for New Dry Syrup Formulation of its Alzheimer's Disease Treatment Aricept | 12-13-11 |
| Lannett Company, Inc. Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules
| 12-13-11 |
| GenVec Inc. President and Chief Executive Officer Announces Retirement | 12-13-11 |
| Catabasis Pharmaceuticals, Inc. Raises VC for Hypertriglyceridemia Treatment | 12-13-11 |
| Daiichi Sankyo, Inc. Release: Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery | 12-13-11 |
| Celgene International S??rl Release: Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA?? and REVLIMID?? in Higher-Risk MDS Patients Presented at American Society of Hematology | 12-13-11 |
| Cubist Pharmaceuticals, Inc. Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Intra-Abdominal Infections | 12-13-11 |
| Celgene International S??rl Release: Phase II Study of ISTODAX?? in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): A Sub-Analysis of Patients with Most Common Subtypes of PTCL Presented at American Society of Hematology
| 12-13-11 |
| Lannett Company, Inc. Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules | 12-13-11 |
| Celgene International S??rl Release: Phase III Study with REVLIMID?? Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma
| 12-13-11 |
| Top-Line Phase 2 Data Indicate Repros Therapeutics Inc.'s Androxal(R) Normalizes Testicular Function in Men With Type 2 Diabetes
| 12-13-11 |
| Two Novartis AG Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna?? Compared to Gleevec?? | 12-13-11 |
| Symphogen A/S Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at American Society of Hematology | 12-13-11 |
| Cell Therapeutics, Inc. and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) | 12-13-11 |
| Onconova Therapeutics Inc. to Present Data Demonstrating Survival Benefit in MDS Patients Treated with Rigosertib and Phase I Data for Oral Rigosertib at the American Society of Hematology Annual Meeting | 12-12-11 |
| Optimer Pharmaceuticals, Inc. Release: The European Commission (EC) Grants Marketing Authorization for DIFICLIR(TM) (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections | 12-12-11 |
| Nektar Therapeutics (CA) Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer | 12-12-11 |
| American Society of Hematology to Present Data Demonstrating Survival Benefit in MDS Patients Treated with Rigosertib and Phase I Data for Oral Rigosertib at the American Society of Hematology Annual Meeting
| 12-12-11 |
| Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR?? for the Treatment of Heart Failure | 12-12-11 |
| Soligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec?? in the Prevention of Acute GVHD | 12-12-11 |
| Rockwell Medical Technologies Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue as Planned | 12-12-11 |
| Sunesis Pharmaceuticals, Inc. Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients | 12-12-11 |
| Micromet??'s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients | 12-12-11 |
| Celator?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the tor?? Pharmaceuticals and the Leukemia & Lymphoma Society?? | 12-12-11 |
| CytRx Corporation Announces the Presentation of Favorable Phase 2 Clinical Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia at American Society of Hematology Conference
| 12-12-11 |
| Theravance, Inc. Announces Initiation of Phase 2 Study With Its MARIN Compound, TD-9855, for the Treatment of ADHD | 12-12-11 |
| Geron Corporation Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer | 12-12-11 |
| Array BioPharma, Inc. Release: ARRY-520 Demonstrates Durable Single-Agent Activity in Patients with Advanced Multiple Myeloma | 12-12-11 |
| University College Dublin and Elan Corporation PLC Announce Initiative to Create Leadership in Biotechnology
| 12-12-11 |
| Breckenridge Pharmaceutical, Inc. Announces Approval of Methscopolamine Bromide Tablets | 12-12-11 |
| Vertex Pharmaceuticals (MA) and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C | 12-09-11 |
| Furiex Pharmaceuticals, Inc. Announces Results for Phase II Trial of PPD-10558 | 12-09-11 |
| Gilead Sciences, Inc. Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV | 12-09-11 |
| Boehringer Mannheim Corporation Completes Patient Entry for Phase III Trial Program in Hepatitis C | 12-09-11 |
| Beijing SL Pharma Buys Stake in Forwell Biopharm for $14 Million | 12-09-11 |
| Galena Biopharma Presents Phase 2 Trial Design for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (Trastuzumab) at the 34th Annual | 12-09-11 |
| Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals, Inc.' VALOR Trial Based on Periodic Safety Review | 12-09-11 |
| Generex Biotechnology Corporation Release: Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at | 12-09-11 |
| Enzon Pharmaceuticals, Inc. Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer | 12-09-11 |
| U.S. Federal Trade Commission Approves LabCorp??'s Acquisition of Orchid Cellmark | 12-09-11 |
| Moberg Derma and Menarini Group Sign Agreement for Emtrix in Italy | 12-09-11 |
| Merck & Co. (Westpoint, PA) in New Agreement with Merck & Co., Inc. to Advance Glycan Biomarker Discovery in Diabetes
| 12-09-11 |
| Vertex Pharmaceuticals Incorporated and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C | 12-09-11 |
| AEterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at | 12-09-11 |
| Boehringer Ingelheim Corporation Completes Patient Entry for Phase III Ttrial Programme in Hepatitis C | 12-09-11 |
| Furiex Pharmaceuticals, Inc. Announces Results for Phase II Trial of PPD-10558
| 12-09-11 |
| NanoString Technologies Inc. Announces Positive Results From First Validation Study of PAM50-based Breast Cancer Assay | 12-09-11 |
